PubMed Health⌕ Search

Biomedical subjects

H Hanus

Publications and source records attributed to H Hanus.

At least 19 recordsLinked to original sources
PubMed1994

[Does juvenile autism have a morphologic basis?].

In the world literature findings of morphological abnormalities in the area of the brain and cerebellum in children with pervasive developmental disorders are encountered. The authors of the present article describe in three case-records morphological abnormalities of the brain and cerebellum found in subjects with markedly expressed or only indicated signs of child autism. At the same time they draw attention to the possible determination of experience and behaviour of subjects with discrete morphological abnormalities, even when the pervasive developmental disorder was not diagnosed but where specific determination of premorbid experience and behaviour, as well as the clinical picture of a possible mental disorder or disease.

Adult↗
PubMed1993

[Treatment of tardive dyskinesias with 7-methoxytacrine. I].

The 7-metoxytacrine (7-MEOTA) is an original Czech cholinergic agent synthetized in the labs of the Military Medical Academy in Hradec Králové. The treatment of tardive dyskinesias is one of the possible indications of the use of 7-MEOTA in clinical practice. The authors have summed up their experience from the first phase of clinical tests with 7-MEOTA in psychiatrical patients suffering from tardive dyskinesias in long-termed administration of cholinergic agents. The clinical efficiency and tolerance of 7-MEOTA have been evaluated after a single administration of 100 mg of 7-MEOTA per os in 19 patients. A reduction of dyskinesias was observed as early as 4 h following the testing dose. In 5 patients, viz. in 26% a reduction of dyskinesias was observed of more than 50% of the original value of the total score of the testing scale AIMS. Except for a slight decrease of the blood pressure and a mild somnolence in 3 patients no other undesirable effects have been observed. In some patients a slight euphorization effect of 7-MEOTA has been found.

Adult↗
PubMed1993

[Treatment of tardive dyskinesias with 7-methoxycrine. II].

In an open clinical study the authors have verified the effectivity and tolerance of 7-metoxytacrine cholinergic agent (7-MEOTA) in a total consisting of 14 patients with schizophrenic or schizoaffective psychoses suffering from tardive dyskinesias in long-termed treatment with neuroleptics. In the whole group consisting of 14 patients the seven days' administration of the experimental preparation in a dose of 100-150 mg pro die was evaluated. The 7-MEOTA preparation was administered to 7 patients for 2 weeks. In the seven and fourteen days' administration a favourable effect of 7-MEOTA on tardive dyskinesias was observed. A fast onset of the efficiency as early as in the first days of the treatment was recorded. In final evaluation a minimal reduction of 50% of the intensity of the dyskinesias (using the AIMS scale) in 29% of the patients treated for a fortnight was found. The 7-MEOTA preparation was well tolerated, no undesirable marked side effects being observed. A transient increase of ALT was found in 1 patient only in the 2nd week of the treatment. In experimental treatment the maintenance neuroleptical therapy was not discontinued. An improvement of the dyskinesias overlasted in some patients as long as 2 month g after the discontinuation of the administration of 7-MEOTA preparation.

Adult↗
PubMed1992

[Huntington's chorea from the viewpoint of forensic psychiatry].

In the initial stages Huntington's chorea is rarely correctly diagnose. The patient however in the early period of the illness is often subjected to social rejection and is more likely to be the victim of criminal acts or the perpetrator of such acts. The article with 3 cases studies concentrates attention to the need to take Huntington's chorea into consideration in determining psychiatric and psychological aspects of tribunals.

Adult↗
PubMed1992

[Prevention of suicidal activity in patients with affective disorders by treatment with lithium].

The authors expressed in 1984 the assumption that lithium is the drug of the phenomenon of suicidal action in affective disorders. In the present paper the authors describe in a group of 56 patients with affective disorders in the course of lithioprophylaxis a marked decline of the suicide rate at the 4% level of significance. Therefore the authors are still in favour of the view that lithium is the drug in suicidal behaviour in affective disorders. This mechanism can be explained by the antiaggressive as well as prophylactic action of lithium. In the authors' opinion it is possible that the mechanism of this action may be conditioned by the interference of lithium with the dysfunction of the central serotonergic system.

Adult↗
PubMed1989

[Lithium in the prevention of affective disorders: 20 years' experience].

Long term preventive lithium administration results are referred to with the manifestation of a full effect in 23% affective illness-related patients. In 70% of patients, the occurrence of side-effects including those initial ones was stated in no but 40% patients in the course of long term lithium-prophylaxis. This fact testifies about the decrease in number of side-effects during the treatment with lithium. Most frequent side-effects were tremors and diarrhea. No serious renal complications were observed, except the onsets of tardive dyskinesis in on patient after the combined administration of chlorprothixene, amitriptyline and lithium. In three patients, the distant relapses were observed without discontinuation of therapy after the 10-year-lasted successful lithium-prophylaxis. In accord to the long term experience, the authors estimate 0.4 mmol/l lithemia level to be the minimal effective one. They believe the lithium is a reliable thymoprophylactic agent, though in accord with them the other substances with larger therapeutic spectrum are to be searched as well as predictors of an effective lithium-prophylaxis.

Affective Disorders, Psychotic↗
PubMed1989

[Initial experience with the administration of 7-methoxyacrine to patients with psychological disorders].

The cholinomimemtic substance 7-methoxyacrine was administered to eight patients, incl. 5 patients with tardive dyskinesias after neuroleptic drugs. In all patients an europhorizing effect was recorded, all five patients with tardive dyskinesias improved markedly after a single dose, in one female patient after repeated administration symptoms of tardive dyskinesia were eliminated. The incidence of side effects is minimal. Based on our modest experience we consider 7-methoxyacrine an important extension of therapeutic possibilities, in particular in tardive dyskinesias. The authors plan to test 7-methoxyacrine also in other indications, in particular in Alzheimer's disease and in side-effects caused by psychopharmaceutical preparations.

Adult↗